by MM360 Staff | Dec 10, 2025 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Dec 10, 2025 | Uncategorized
Source: CURE articles Post Content Read More
by Josh Friedman | Dec 9, 2025 | Uncategorized
ORLANDO — “The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for disease progression or death 83% from standard...
by MM360 Staff | Dec 9, 2025 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Dec 7, 2025 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Dec 7, 2025 | Uncategorized
Source: CURE articles Post Content Read More